Regarding the transformation of MDS and MPN to AML, loss of EZH2 function also appears to play an ambiguous role, being able to attenuate and promote leukemic transformation depending on the disease context and cooperating mutations [11, 13, 14]. This evidence concerns the gene EZH2 and myeloproliferative disorder.